```html

Eczema Herpeticum: A Complete Guide for Patients

Overview

Eczema herpeticum (also called Kaposi’s varicelliform eruption) is a rare, potentially severe skin infection caused by the herpes simplex virus (HSV) spreading across areas of pre‑existing atopic dermatitis (eczema) or other skin barrier disorders. While most people are familiar with “cold sores” or genital herpes, eczema herpeticum represents a disseminated form of HSV that can involve large skin surfaces, leading to fever, malaise, and, in extreme cases, systemic infection.

Who it affects: The condition most commonly occurs in children and adolescents with moderate‑to‑severe atopic dermatitis, but adults with compromised skin barriers (e.g., due to psoriasis, burns, or chronic wounds) are also at risk. Immunocompromised patients—those on systemic steroids, biologic agents, or chemotherapy—have a higher likelihood of developing the infection.

Prevalence: Epidemiologic data are limited because the condition is uncommon, but studies estimate that 3–10 % of patients with severe atopic dermatitis will develop eczema herpeticum at some point in their lives.<sup>[1] CDC, 2022</sup> In pediatric dermatology clinics, the incidence is reported to be about 1–2 % per year among children with active eczema.<sup>[2] Mayo Clinic, 2023</sup>

Symptoms

Eczema herpeticum typically appears abruptly and progresses quickly. The hallmark features include:

• Clustered vesicles or pustules that start as small, clear fluid‑filled blisters and become umbilicated, then rupture to form “crusted” lesions.
• Uniform, monomorphic appearance—unlike typical eczema flares, the lesions look the same size and shape across the affected area.
• Rapid spread—new lesions can appear within hours, often following a line of skin trauma (Kirby‑Brown line).
• Fever & malaise—systemic symptoms such as temperature >38 °C (100.4 °F), chills, headache, and fatigue are common.
• Localized pain or burning at the site of lesions.
• Swollen lymph nodes near the affected area (e.g., cervical nodes for facial lesions).
• Oral involvement—if herpes labialis spreads, you may notice painful ulcers on the lips or inside the mouth.
• Eye involvement—rare but serious; conjunctivitis or keratitis can develop when lesions affect the peri‑ocular skin.
• Neurologic signs in severe cases—headache, confusion, or seizures may indicate viral encephalitis.

Because the lesions can become secondarily infected with bacteria such as *Staphylococcus aureus*, patients may also develop signs of bacterial cellulitis (increased redness, warmth, pus).

Causes and Risk Factors

Primary cause

Eczema herpeticum is caused by infection with Herpes Simplex Virus type 1 (HSV‑1) in the overwhelming majority of cases, and less frequently by HSV‑2.<sup>[3] WHO, 2021</sup> The virus gains entry through breaks in the skin barrier—common in atopic dermatitis due to scratching, excoriation, or secondary infections.

Key risk factors

• Severe or poorly controlled atopic dermatitis—especially when the skin is weeping or oozing.
• Recent use of systemic corticosteroids or immunosuppressants (e.g., methotrexate, cyclosporine, biologics such as dupilumab).
• Young age—children under 5 have the highest incidence.
• History of HSV infection—most patients have prior cold sores, even if they are unaware.
• Skin trauma—scratches, burns, surgical wounds, or even harsh topical treatments.
• Other skin diseases—psoriasis, ichthyosis, or chronic wounds can serve as portals.
• Immunodeficiency—HIV infection, primary immunodeficiency, or organ transplantation.

Diagnosis

Early recognition is essential because delayed treatment can lead to systemic illness. Diagnosis combines clinical assessment with targeted laboratory testing.

Clinical examination

• Evaluation of lesion morphology (uniform vesiculopustules on eczematous skin).
• Assessment for systemic signs (fever, lymphadenopathy).
• Documentation of distribution—common sites include the face, neck, trunk, and extremities.

Laboratory and bedside tests

• Tzanck smear—scraping the base of a fresh vesicle. Multinucleated giant cells suggest HSV infection, though specificity is moderate.
• Viral culture—gold standard but takes 2–3 days; less frequently used now.
• Polymerase chain reaction (PCR) of lesion swab—highly sensitive and specific; preferred in most centers.
• HSV serology—helps confirm prior exposure but does not differentiate active infection.
• Complete blood count (CBC) and metabolic panel—may reveal leukocytosis or electrolyte disturbances in severe disease.

Differential diagnosis

Other conditions that can mimic eczema herpeticum include impetigo, varicella‑zoster infection, contact dermatitis, and bullous pemphigoid. Laboratory confirmation helps avoid misdiagnosis.

Treatment Options

Management aims to eradicate HSV, control inflammation, prevent bacterial superinfection, and address the underlying skin barrier defect.

Antiviral therapy (first‑line)

• Acyclovir 400 mg PO every 5 hours (or 800 mg PO five times daily) for 7‑10 days. Intravenous (IV) acyclovir 5–10 mg/kg every 8 hours is indicated for severe or systemic disease.<sup>[4] NIH, 2022</sup>
• Valacyclovir 1 g PO twice daily or 500 mg three times daily (less frequent dosing, good bioavailability).
• Famciclovir 500 mg PO three times daily as an alternative.
• Therapy should be started as soon as possible—ideally within 24 hours of lesion onset—to reduce complications.

Adjunctive treatments

• Topical antibiotics (e.g., mupirocin) when secondary bacterial infection is suspected.
• Systemic antibiotics (e.g., cephalexin or clindamycin) guided by culture if cellulitis develops.
• Short courses of systemic steroids are controversial; they may blunt inflammation but can worsen viral replication. Most experts avoid steroids during active HSV infection.
• Moisturizers & barrier repairs—fragrance‑free emollients, ceramide‑containing creams, and non‑irritating cleansers to support healing.

Procedural considerations

In rare, resistant cases, intravenous immunoglobulin (IVIG) or experimental antiviral agents (e.g., brincidofovir) have been reported, typically in immunocompromised hosts.

Follow‑up care

Patients should be re‑evaluated within 48‑72 hours of starting antivirals to ensure clinical improvement (decreasing lesion count, fever resolution) and to adjust therapy if needed.

Living with Eczema Herpeticum

Even after the acute infection resolves, many patients continue to struggle with atopic dermatitis. Below are practical strategies to minimize flare‑ups and promote skin health.

Skin‑care routine

• Apply a thick, fragrance‑free moisturizer at least twice daily; consider ointments (petrolatum, lanolin) for very dry areas.
• Use a gentle, pH‑balanced cleanser (e.g., cetyl alcohol‑based) and avoid hot water.
• After bathing, pat skin dry—do not rub—to preserve the lipid barrier.

Itch control

• Identify and avoid triggers (wool, certain soaps, allergens).
• Use anti‑itch topicals such as 1 % hydrocortisone or calcineurin inhibitors (tacrolimus 0.1 % ointment) under physician guidance.
• Consider antihistamines (e.g., cetirizine) at night to reduce scratching during sleep.

Medication adherence

Complete the full antiviral course even if lesions improve early. Skipping doses can lead to viral resistance.

Monitoring for recurrence

• Keep a journal of flare patterns, triggers, and any cold‑sore outbreaks.
• Promptly report new vesicles to your clinician, especially if you have a known history of eczema herpeticum.

Psychosocial support

Visible skin lesions can affect self‑esteem. Counseling, support groups, or dermatology‑focused mental‑health resources can be valuable.

Prevention

Because eczema herpeticum arises from HSV infection of compromised skin, prevention focuses on both viral exposure and skin barrier protection.

• Vaccination—while there is no HSV vaccine, routine immunizations such as the varicella vaccine prevent confounding viral rashes.
• Hand hygiene—wash hands frequently, especially after touching the face or lesions.
• Avoid sharing personal items (towels, razors, lip balm) with anyone who has active cold sores.
• Prophylactic antivirals—for patients with recurrent eczema herpeticum, low‑dose daily acyclovir or valacyclovir may be prescribed after specialist consultation.
• Skin barrier maintenance—consistent moisturization, avoidance of harsh soaps, and prompt treatment of eczema flares.
• Early treatment of HSV infections—initiate antiviral therapy at the first sign of a cold sore to reduce viral load.
• Control of atopic dermatitis—regular follow‑up with a dermatologist or allergist to optimize topical and, when appropriate, systemic therapies.

Complications

If left untreated or inadequately managed, eczema herpeticum can lead to serious outcomes:

• Disseminated HSV infection—spread to internal organs (lungs, liver, brain).
• Viral encephalitis—rare but life‑threatening, presenting with seizures or altered mental status.
• Secondary bacterial infection—often with MRSA or Streptococcus pyogenes, potentially causing cellulitis or abscesses.
• Scarring and dyspigmentation—especially if lesions ulcerate or are improperly managed.
• Ocular involvement—keratitis or conjunctivitis can lead to permanent vision loss.
• Systemic sepsis—particularly in immunocompromised patients.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Herpes Simplex Virus Infection (HSV).” Updated 2022. https://www.cdc.gov/herpes
2. Mayo Clinic. “Eczema herpeticum.” Patient care guide, 2023. https://www.mayoclinic.org
3. World Health Organization. “Herpesvirus infections.” Fact sheet, 2021. https://www.who.int
4. National Institutes of Health. “Clinical Guidelines for the Management of Herpes Simplex Virus.” 2022. https://www.ncbi.nlm.nih.gov
5. Cleveland Clinic. “Eczema Herpeticum (Kaposi Varicelliform Eruption).” 2023. https://my.clevelandclinic.org

```